Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 18/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077795 | 0.94 | GCK (0.35) | GCK | |
| SCHEMBL1677219 | 0.94 | GCK (0.39) | GCKKCNH2ABL1 | |
| SCHEMBL12734449 | 0.94 | GCK (0.33) | GCK | |
| SCHEMBL1677365 | 0.92 | GCK (0.39) | GCKKCNH2ABL1 | |
| SCHEMBL12807221 | 0.92 | GCK (0.37) | GCKKCNH2ABL1 | |
| SCHEMBL12807204 | 0.92 | GCK (0.37) | GCKKCNH2ABL1 | |
| SCHEMBL1076656 | 0.91 | GCK (0.38) | GCKKCNH2ABL1 | |
| SCHEMBL1077325 | 0.91 | GCK (0.38) | GCKKCNH2ABL1 | |
| SCHEMBL1677907 | 0.91 | GCK (0.35) | GCK | |
| SCHEMBL1677383 | 0.90 | GCK (0.42) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| WO-2009125873-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | GCK 4/4885KCNH2 2388/4885ABL1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.